What are the risks and contraindications associated with norethindrone therapy?

Risks of Norethindrone Treatment

Norethindrone carries significant contraindications including thromboembolic disease, breast cancer, hepatic disease, and pregnancy (Category X), with common adverse effects including irregular bleeding, headache, and mood changes. 1

Absolute Contraindications

Norethindrone-containing formulations are absolutely contraindicated in the following conditions 1:

• Thromboembolic disease: Active or history of deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction
• Malignancies: Breast cancer, endometrial carcinoma, or other estrogen/progestin-sensitive cancers
• Hepatic disease: Active hepatic dysfunction, hepatic adenomas or carcinomas, cholestatic jaundice
• Cardiovascular disease: Cerebrovascular disease, coronary artery disease, uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg)
• Pregnancy: Category X - absolutely contraindicated 1
• Undiagnosed genital bleeding 1
• Anaphylactic reaction or angioedema to the medication 1

Cardiovascular and Cerebrovascular Risks

Stroke Risk

When norethindrone is combined with ethinyl estradiol, stroke risk increases in a dose-dependent manner. 1 For every 10 μg increase in estrogen content, the odds ratio for stroke increases by 1.19 (95% CI, 1.16–1.23) 1. Combined oral contraceptives containing norethindrone with estrogen show increased stroke risk, particularly in women with additional risk factors 1.

Progestin-only norethindrone formulations (without estrogen) do not carry the same stroke risk as combined formulations. 1 The 2024 American Heart Association/American Stroke Association guidelines specifically note that progestin-only pills containing norethindrone have no increased stroke risk 1.

Hypertension

Norethindrone-containing combined hormonal contraceptives can elevate blood pressure, with historical studies showing increases of 7-17 mmHg systolic and 3-11 mmHg diastolic. 1 Blood pressure monitoring is required at baseline and during ongoing treatment 1.

Venous Thromboembolism (VTE)

Combined formulations with norethindrone carry a moderately increased VTE risk that appears dose-dependent. 1, 2 Contraceptive doses carry minimal risk, but therapeutic doses (higher than contraceptive dosing) may be associated with increased VTE risk 2. The absolute VTE risk remains lower than pregnancy-associated VTE risk (5-20 per 10,000 person-years in pregnancy versus 3-9 in combined oral contraceptive users) 1.

Common Adverse Effects

Menstrual Irregularities

Irregular bleeding is the most common adverse effect and the leading cause of discontinuation. 1, 3, 4 In adolescent populations, 54.5% of discontinuations were due to irregular bleeding 4. Progestin-only formulations cause irregular menstrual patterns in the majority of users 3.

Central Nervous System Effects

• Headache, depression, and nervousness are commonly reported 1
• Mood disorders may occur, particularly with long-acting formulations 5
• Postnatal administration of long-acting norethisterone enanthate significantly increased depression scores (mean MADRS 8.3 vs 4.9 in placebo; P=0.0111) 5

Gastrointestinal Effects

• Nausea, vomiting, abdominal pain, and dyspepsia 1
• Hepatotoxicity is a rare but serious adverse effect 6

Endocrine Effects

• Breast pain or tenderness 1
• Weight changes 1
• Menorrhagia or amenorrhea 1

Serious Adverse Events

Hepatotoxicity

Norethindrone can cause transaminitis (elevated liver enzymes), which resolves upon discontinuation. 6 A case series of 10 patients showed ALT/AST elevations occurring at various time points, with normalization within 1-12 months after stopping the medication 6. Higher doses (10 mg daily) showed quicker resolution (average 4 months) 6.

Monitoring liver function is essential, even in asymptomatic patients. 6

Ectopic Pregnancy Risk

The incidence of ectopic pregnancy in progestin-only oral contraceptive users is 5 per 1,000 woman-years. 3 Up to 10% of pregnancies in progestin-only pill users are extrauterine 3. Healthcare providers must remain alert to lower abdominal pain in users who become pregnant 3.

Ovarian Cysts

Delayed follicular atresia may occur, causing enlarged ovarian cysts. 3 These generally resolve spontaneously but may occasionally require surgical intervention if they twist or rupture 3.

Cancer Risks

Breast Cancer

Some epidemiologic studies report increased relative risk of breast cancer with oral contraceptive use, particularly with younger age and longer duration. 3 However, insufficient data exist to determine whether progestin-only pills similarly increase risk 3. Women with breast cancer should not use norethindrone 3.

Cervical Cancer

Oral contraceptive use may be associated with increased risk of cervical intraepithelial neoplasia, though causality remains controversial. 3 Insufficient data exist for progestin-only formulations 3.

Special Populations

Breastfeeding

The World Health Organization recommends avoiding breastfeeding if possible with norethindrone/ethinyl estradiol combinations, as infant risk cannot be ruled out. 1 However, norethindrone alone and norgestimate combinations are considered compatible with breastfeeding 1.

Progestin-only norethindrone (0.35 mg/day) in breastfeeding Latino women was associated with a 2-3 fold increase in diabetes risk. 1 Use with caution during breastfeeding in this population 1.

Pediatric Use

Safety and efficacy are not established for norethindrone/ethinyl estradiol combinations in patients under 15 years. 1 Use before menarche is not indicated 1.

Gestational Diabetes History

Women with prior gestational diabetes should use progestin-only agents with caution during breastfeeding due to increased diabetes risk. 1

Drug Interactions

Norethindrone has extensive drug interactions that may reduce contraceptive efficacy or increase toxicity 1:

• Anticonvulsants (barbiturates, carbamazepine, phenytoin, topiramate) - reduce efficacy
• Antibiotics (rifampin, some macrolides, penicillins, tetracyclines) - may reduce efficacy
• Antiretrovirals - variable effects on both contraceptive and ARV levels 1
• St. John's Wort - reduces efficacy 1
• Anticoagulants - norethindrone may affect anticoagulant activity 1

Monitoring Requirements

Baseline assessment must include: 1

• Pregnancy status verification
• Blood pressure measurement
• Breast and pelvic examinations (for combined formulations)

Ongoing monitoring requires: 1

• Blood pressure checks
• Assessment of health status changes
• Liver function monitoring, particularly with higher doses 6

Clinical Pitfalls

The most critical pitfall is failing to recognize that norethindrone partially converts to ethinyl estradiol. 2 Doses of 10-20 mg norethindrone correspond to 20-30 μg ethinyl estradiol 2. This conversion means therapeutic doses carry estrogen-related risks including thrombosis and stroke, particularly in women with migraine with aura 2.

Smoking dramatically increases cardiovascular risks. 3 Women who use oral contraceptives containing norethindrone are strongly advised not to smoke 3.